Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma
Abstract The anticancer effects of human amniotic membrane (hAM) have been studied over the last decade. However, the action mechanisms responsible for these effects are not fully understood until now. Previously results reported by our team proved that hAM is able to induce cytotoxicity and cell death in hepatocellular carcinoma (HCC), a worldwide high incident and mortal cancer. Therefore, this experimental study aimed to investigate the cellular targets of hAM protein extracts (hAMPE) in HCC through in vitro studies. Our results showed that hAMPE is able to modify oxidative stress environment in all HCC cell lines, as well as its cell cycle. hAMPE differently targets deoxyribonucleic acid (DNA), P21, P53, β-catenin and multidrug resistance (MDR) proteins in HCC cell lines. In conclusion, hAMPE has several targets in HCC, being clear that the success of this treatment depends of a personalized therapy based on the biological and genetic characteristics of the tumor..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Pathology & oncology research - 22(2016), 4 vom: 10. März, Seite 689-697 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mamede, A. C. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Cell cycle |
|---|
| Anmerkungen: |
© Arányi Lajos Foundation 2016 |
|---|
| doi: |
10.1007/s12253-016-0053-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR025076620 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR025076620 | ||
| 003 | DE-627 | ||
| 005 | 20230519100718.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201007s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12253-016-0053-x |2 doi | |
| 035 | |a (DE-627)SPR025076620 | ||
| 035 | |a (SPR)s12253-016-0053-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mamede, A. C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oxidative Stress, DNA, Cell Cycle/Cell Cycle Associated Proteins and Multidrug Resistance Proteins: Targets of Human Amniotic Membrane in Hepatocellular Carcinoma |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Arányi Lajos Foundation 2016 | ||
| 520 | |a Abstract The anticancer effects of human amniotic membrane (hAM) have been studied over the last decade. However, the action mechanisms responsible for these effects are not fully understood until now. Previously results reported by our team proved that hAM is able to induce cytotoxicity and cell death in hepatocellular carcinoma (HCC), a worldwide high incident and mortal cancer. Therefore, this experimental study aimed to investigate the cellular targets of hAM protein extracts (hAMPE) in HCC through in vitro studies. Our results showed that hAMPE is able to modify oxidative stress environment in all HCC cell lines, as well as its cell cycle. hAMPE differently targets deoxyribonucleic acid (DNA), P21, P53, β-catenin and multidrug resistance (MDR) proteins in HCC cell lines. In conclusion, hAMPE has several targets in HCC, being clear that the success of this treatment depends of a personalized therapy based on the biological and genetic characteristics of the tumor. | ||
| 650 | 4 | |a Human amniotic membrane |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hepatocellular carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Protein extracts |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a hAMPE |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Oxidative stress |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cell cycle |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Guerra, S. |4 aut | |
| 700 | 1 | |a Laranjo, M. |4 aut | |
| 700 | 1 | |a Santos, K. |4 aut | |
| 700 | 1 | |a Carvalho, M. J. |4 aut | |
| 700 | 1 | |a Carvalheiro, T. |4 aut | |
| 700 | 1 | |a Moura, P. |4 aut | |
| 700 | 1 | |a Paiva, A. |4 aut | |
| 700 | 1 | |a Abrantes, A. M. |4 aut | |
| 700 | 1 | |a Maia, C. J. |4 aut | |
| 700 | 1 | |a Botelho, M. F. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathology & oncology research |d Heidelberg : Springer, 1995 |g 22(2016), 4 vom: 10. März, Seite 689-697 |w (DE-627)SPR025050133 |w (DE-600)2002501-4 |x 1532-2807 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2016 |g number:4 |g day:10 |g month:03 |g pages:689-697 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12253-016-0053-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2016 |e 4 |b 10 |c 03 |h 689-697 | ||